Nine-weeks of adjuvant trastuzumab in HER2-positive breast cancer: A single center experience

Kizilarslanoglu C., Petekkaya I., Babacan T., Altundag K.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30 identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 30
  • City: Illinois
  • Country: United States Of America
  • Hacettepe University Affiliated: Yes